Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 2Phase 2 2Phase 1 2Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Breast Neoplasms 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Anthracyclines × Clear all
NCT06332508 2026-03-13

Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)

National University Hospital, Singapore

Phase 1 Completed
14 enrolled
Breast

Breast Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

Merck Sharp & Dohme LLC

Phase 1 Completed
60 enrolled 26 charts
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡